Thomas Handeguand, DO
Family Medicine · Phoenix, AZNPI 1548347305
Payments from drug & device makers
Across 222 payments — averaging $14.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Boehringer Ingelheim$301
- Abbott$183
- Novo Nordisk$141
- AstraZeneca$138
- Johnson & Johnson$138
- plus $855 from 17 others
What the payments were for
- Food & beverage$3,10098%
- Education$512%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 137 | $1,395 |
| Boehringer Ingelheim | 17 | $301 |
| Abbott | 7 | $183 |
| Novo Nordisk | 8 | $141 |
| AstraZeneca | 4 | $138 |
| Johnson & Johnson | 5 | $138 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $134 |
| Pfizer | 7 | $116 |
| Boston Scientific | 2 | $111 |
| Lilly USA, LLC | 7 | $107 |
| Amgen | 2 | $61 |
| Sanofi-aventis U.S. LLC | 1 | $51 |
| Novartis | 3 | $50 |
| Astellas Pharma US Inc | 2 | $39 |
| Hikma Pharmaceuticals USA | 2 | $34 |
| Almatica Pharma LLC | 2 | $26 |
| Idorsia Pharmaceuticals US Inc | 2 | $26 |
| Philips North America LLC | 1 | $22 |
| GSK | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Bayer | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
How this compares
$3,151 in reported general payments places this provider in the 85th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 59 | $87,798 |
| OzempicSemaglutide | 30 | $30,721 |
| FarxigaDapagliflozin Propanediol | 22 | $30,000 |
| MounjaroTirzepatide | 22 | $29,351 |
| QuliptaAtogepant | 15 | $20,347 |
| XareltoRivaroxaban | 11 | $15,665 |
| Spiriva RespimatTiotropium Bromide | 12 | $10,068 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 136 | $3,150 |
| Rosuvastatin Calcium | 156 | $2,751 |
| Wixela InhubFluticasone Propion/Salmeterol | 14 | $2,462 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $2,241 |
| Gabapentin | 81 | $2,053 |
| Atorvastatin Calcium | 210 | $1,768 |
| Verapamil ErVerapamil Hcl | 44 | $1,657 |
| Losartan Potassium | 193 | $1,624 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $301 | $97,86771 claims |
| Novo NordiskOzempic | $141 | $30,72130 claims |
| AstraZenecaFarxiga | $138 | $30,00022 claims |
| Lilly USA, LLCMounjaro | $107 | $29,35122 claims |
| AbbVieQulipta | $1,395 | $20,34715 claims |
| Johnson & JohnsonXarelto | $138 | $15,66511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Phoenix
- Brock MerrittPhoenix$8.4M
- Douglas CunninghamPhoenix$4.9M
- Jeffrey ZacherPhoenix$2M
- Trisha TavaresPhoenix$1.6M
- David FrancykPhoenix$1.3M
- James BeachPhoenix$1.2M
- Peter LevinsPhoenix$971K
- Elysa ShawPhoenix$774K
- Mitchell EdelsteinPhoenix$741K
- Brian DedinskyPhoenix$589K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.